Skip to main content
. 2015 Oct 21;21(39):11168–11178. doi: 10.3748/wjg.v21.i39.11168

Figure 4.

Figure 4

Plasma interleukin-6 levels in pancreatic ductal adenocarcinoma patients receiving chemoimmunotherapy. A: Plasma interleukin (IL)-6 levels in 6 patients during treatment; B: Comparison of plasma IL-6 levels prior to treatment between super-responders [overall survival (OS) ≥ 1 year] and nonsuper-responders (OS < 1 year); C: Comparison of plasma IL-6 levels in super-responders prior to treatment and post-vaccination; D: Comparison of plasma IL-6 levels after 5 vaccinations between nonsuper-responders and super-responders after 5, 10, 15, 20, and 25 vaccinations. The values are expressed as mean ± SD. aP < 0.05.